Annual FCF
$747.60 M
+$83.90 M+12.64%
31 December 2023
Summary:
United Therapeutics annual free cash flow is currently $747.60 million, with the most recent change of +$83.90 million (+12.64%) on 31 December 2023. During the last 3 years, it has risen by +$51.20 million (+7.35%). UTHR annual FCF is now at all-time high.UTHR Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$300.70 M
+$113.60 M+60.72%
30 September 2024
Summary:
United Therapeutics quarterly free cash flow is currently $300.70 million, with the most recent change of +$113.60 million (+60.72%) on 30 September 2024. Over the past year, it has increased by +$20.20 million (+7.20%). UTHR quarterly FCF is now -11.11% below its all-time high of $338.30 million, reached on 31 March 2024.UTHR Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$898.10 M
+$20.20 M+2.30%
30 September 2024
Summary:
United Therapeutics TTM free cash flow is currently $898.10 million, with the most recent change of +$20.20 million (+2.30%) on 30 September 2024. Over the past year, it has increased by +$133.80 million (+17.51%). UTHR TTM FCF is now at all-time high.UTHR TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
UTHR Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.6% | +7.2% | +17.5% |
| 3 y3 years | +7.3% | +85.3% | +84.3% |
| 5 y5 years | +25.9% | +75.0% | +368.5% |
UTHR Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +56.6% | -11.1% | +388.1% | at high | +88.1% |
| 5 y | 5 years | at high | +357.5% | -11.1% | +388.1% | at high | +368.5% |
| alltime | all time | at high | +357.5% | -11.1% | +146.1% | at high | +368.5% |
United Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $300.70 M(+60.7%) | $898.10 M(+2.3%) |
| June 2024 | - | $187.10 M(-44.7%) | $877.90 M(+16.7%) |
| Mar 2024 | - | $338.30 M(+369.9%) | $752.40 M(+0.6%) |
| Dec 2023 | $747.60 M(+12.6%) | $72.00 M(-74.3%) | $747.60 M(-2.2%) |
| Sept 2023 | - | $280.50 M(+355.4%) | $764.30 M(+13.5%) |
| June 2023 | - | $61.60 M(-81.5%) | $673.60 M(-6.7%) |
| Mar 2023 | - | $333.50 M(+276.0%) | $722.00 M(+8.8%) |
| Dec 2022 | $663.70 M(+39.0%) | $88.70 M(-53.3%) | $663.70 M(-2.3%) |
| Sept 2022 | - | $189.80 M(+72.5%) | $679.00 M(+4.2%) |
| June 2022 | - | $110.00 M(-60.0%) | $651.50 M(-3.3%) |
| Mar 2022 | - | $275.20 M(+164.6%) | $673.40 M(+41.1%) |
| Dec 2021 | $477.40 M(-31.4%) | $104.00 M(-35.9%) | $477.40 M(-2.0%) |
| Sept 2021 | - | $162.30 M(+23.0%) | $487.30 M(-13.0%) |
| June 2021 | - | $131.90 M(+66.5%) | $560.10 M(-2.4%) |
| Mar 2021 | - | $79.20 M(-30.5%) | $574.00 M(-17.6%) |
| Dec 2020 | $696.40 M(-339.9%) | $113.90 M(-51.6%) | $696.40 M(+5.5%) |
| Sept 2020 | - | $235.10 M(+61.2%) | $660.30 M(+10.6%) |
| June 2020 | - | $145.80 M(-27.7%) | $597.00 M(+5.9%) |
| Mar 2020 | - | $201.60 M(+159.1%) | $563.80 M(-294.2%) |
| Dec 2019 | -$290.30 M(-148.9%) | $77.80 M(-54.7%) | -$290.30 M(-13.2%) |
| Sept 2019 | - | $171.80 M(+52.6%) | -$334.50 M(+7.8%) |
| June 2019 | - | $112.60 M(-117.3%) | -$310.30 M(+4.6%) |
| Mar 2019 | - | -$652.50 M(-2042.0%) | -$296.60 M(-149.9%) |
| Dec 2018 | $594.00 M(+53.1%) | $33.60 M(-82.9%) | $594.00 M(+32.9%) |
| Sept 2018 | - | $196.00 M(+55.2%) | $446.80 M(-8.3%) |
| June 2018 | - | $126.30 M(-47.0%) | $487.30 M(+18.6%) |
| Mar 2018 | - | $238.10 M(-309.6%) | $410.80 M(+5.9%) |
| Dec 2017 | $387.90 M(-35.9%) | -$113.60 M(-148.0%) | $387.90 M(-40.8%) |
| Sept 2017 | - | $236.50 M(+374.9%) | $655.40 M(+2.6%) |
| June 2017 | - | $49.80 M(-76.9%) | $638.50 M(-9.3%) |
| Mar 2017 | - | $215.20 M(+39.8%) | $704.00 M(+16.2%) |
| Dec 2016 | $605.60 M(+81.9%) | $153.90 M(-29.9%) | $605.60 M(+35.9%) |
| Sept 2016 | - | $219.60 M(+90.5%) | $445.70 M(+5.4%) |
| June 2016 | - | $115.30 M(-1.3%) | $422.80 M(+22.7%) |
| Mar 2016 | - | $116.80 M(-2046.7%) | $344.70 M(+3.5%) |
| Dec 2015 | $333.00 M(+8.2%) | -$6.00 M(-103.1%) | $333.00 M(-22.1%) |
| Sept 2015 | - | $196.70 M(+428.8%) | $427.40 M(+0.4%) |
| June 2015 | - | $37.20 M(-64.6%) | $425.60 M(+32.6%) |
| Mar 2015 | - | $105.10 M(+18.9%) | $321.08 M(+4.3%) |
| Dec 2014 | $307.90 M(-21.7%) | $88.40 M(-54.6%) | $307.90 M(-0.8%) |
| Sept 2014 | - | $194.89 M(-389.5%) | $310.50 M(+26.5%) |
| June 2014 | - | -$67.32 M(-173.2%) | $245.50 M(-37.3%) |
| Mar 2014 | - | $91.92 M(+1.0%) | $391.82 M(-0.4%) |
| Dec 2013 | $393.36 M(+85.8%) | $91.01 M(-29.9%) | $393.36 M(+1.8%) |
| Sept 2013 | - | $129.88 M(+64.4%) | $386.30 M(+12.6%) |
| June 2013 | - | $79.01 M(-15.5%) | $343.14 M(+11.5%) |
| Mar 2013 | - | $93.45 M(+11.3%) | $307.88 M(+45.4%) |
| Dec 2012 | $211.72 M(-1.2%) | $83.95 M(-3.2%) | $211.72 M(+17.5%) |
| Sept 2012 | - | $86.72 M(+98.2%) | $180.15 M(+15.3%) |
| June 2012 | - | $43.75 M(-1722.1%) | $156.26 M(-5.0%) |
| Mar 2012 | - | -$2.70 M(-105.1%) | $164.50 M(-23.2%) |
| Dec 2011 | $214.22 M | $52.38 M(-16.6%) | $214.22 M(+9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $62.84 M(+20.9%) | $195.65 M(-15.5%) |
| June 2011 | - | $51.99 M(+10.6%) | $231.56 M(+9.2%) |
| Mar 2011 | - | $47.02 M(+39.1%) | $212.05 M(+9.9%) |
| Dec 2010 | $192.89 M(+4362.0%) | $33.81 M(-65.8%) | $192.89 M(+17.7%) |
| Sept 2010 | - | $98.75 M(+204.0%) | $163.90 M(+187.1%) |
| June 2010 | - | $32.48 M(+16.6%) | $57.08 M(+15.5%) |
| Mar 2010 | - | $27.86 M(+478.5%) | $49.41 M(+1043.0%) |
| Dec 2009 | $4.32 M(-102.5%) | $4.82 M(-159.7%) | $4.32 M(-102.6%) |
| Sept 2009 | - | -$8.07 M(-132.5%) | -$163.99 M(-11.6%) |
| June 2009 | - | $24.81 M(-244.0%) | -$185.53 M(-12.8%) |
| Mar 2009 | - | -$17.23 M(-89.5%) | -$212.68 M(+22.5%) |
| Dec 2008 | -$173.61 M(-1787.3%) | -$163.50 M(+452.1%) | -$173.61 M(+330.6%) |
| Sept 2008 | - | -$29.61 M(+1168.3%) | -$40.32 M(-533.7%) |
| June 2008 | - | -$2.33 M(-110.7%) | $9.30 M(-64.6%) |
| Mar 2008 | - | $21.84 M(-172.3%) | $26.26 M(+155.3%) |
| Dec 2007 | $10.29 M(-69.5%) | -$30.21 M(-251.0%) | $10.29 M(-67.2%) |
| Sept 2007 | - | $20.00 M(+36.7%) | $31.41 M(+21.5%) |
| June 2007 | - | $14.63 M(+149.7%) | $25.85 M(+6.6%) |
| Mar 2007 | - | $5.86 M(-164.5%) | $24.24 M(-28.2%) |
| Dec 2006 | $33.75 M(-8.9%) | -$9.09 M(-162.9%) | $33.75 M(-30.3%) |
| Sept 2006 | - | $14.44 M(+10.9%) | $48.46 M(-0.5%) |
| June 2006 | - | $13.02 M(-15.3%) | $48.69 M(+2.0%) |
| Mar 2006 | - | $15.38 M(+173.7%) | $47.72 M(+28.8%) |
| Dec 2005 | $37.05 M(+138.1%) | $5.62 M(-61.7%) | $37.05 M(+9.6%) |
| Sept 2005 | - | $14.68 M(+21.8%) | $33.81 M(+20.1%) |
| June 2005 | - | $12.05 M(+155.8%) | $28.16 M(+38.0%) |
| Mar 2005 | - | $4.71 M(+98.3%) | $20.40 M(+31.1%) |
| Dec 2004 | $15.56 M(-200.0%) | $2.38 M(-73.7%) | $15.56 M(-808.9%) |
| Sept 2004 | - | $9.03 M(+110.5%) | -$2.19 M(-70.4%) |
| June 2004 | - | $4.29 M(-3502.4%) | -$7.42 M(-47.8%) |
| Mar 2004 | - | -$126.00 K(-99.2%) | -$14.20 M(-8.8%) |
| Dec 2003 | -$15.57 M(-39.8%) | -$15.38 M(-504.7%) | -$15.57 M(+1727.0%) |
| Sept 2003 | - | $3.80 M(-252.3%) | -$852.00 K(-93.6%) |
| June 2003 | - | -$2.50 M(+67.3%) | -$13.36 M(-27.2%) |
| Mar 2003 | - | -$1.49 M(+123.5%) | -$18.34 M(-29.0%) |
| Dec 2002 | -$25.84 M(-34.7%) | -$667.00 K(-92.3%) | -$25.84 M(-21.2%) |
| Sept 2002 | - | -$8.70 M(+16.4%) | -$32.80 M(-9.3%) |
| June 2002 | - | -$7.48 M(-16.9%) | -$36.17 M(-9.1%) |
| Mar 2002 | - | -$8.99 M(+17.9%) | -$39.79 M(+0.5%) |
| Dec 2001 | -$39.59 M(+24.7%) | -$7.63 M(-36.8%) | -$39.59 M(-6.3%) |
| Sept 2001 | - | -$12.08 M(+8.9%) | -$42.26 M(+19.5%) |
| June 2001 | - | -$11.09 M(+26.3%) | -$35.37 M(+6.3%) |
| Mar 2001 | - | -$8.79 M(-14.7%) | -$33.28 M(+4.8%) |
| Dec 2000 | -$31.75 M(+22.1%) | -$10.30 M(+98.6%) | -$31.75 M(+7.4%) |
| Sept 2000 | - | -$5.19 M(-42.4%) | -$29.56 M(-6.1%) |
| June 2000 | - | -$9.01 M(+24.1%) | -$31.47 M(+4.3%) |
| Mar 2000 | - | -$7.26 M(-10.4%) | -$30.16 M(+16.0%) |
| Dec 1999 | -$26.00 M(+145.3%) | -$8.10 M(+14.1%) | -$26.00 M(+45.3%) |
| Sept 1999 | - | -$7.10 M(-7.8%) | -$17.90 M(+65.7%) |
| June 1999 | - | -$7.70 M(+148.4%) | -$10.80 M(+248.4%) |
| Mar 1999 | - | -$3.10 M | -$3.10 M |
| Dec 1998 | -$10.60 M | - | - |
FAQ
- What is United Therapeutics annual free cash flow?
- What is the all time high annual FCF for United Therapeutics?
- What is United Therapeutics annual FCF year-on-year change?
- What is United Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for United Therapeutics?
- What is United Therapeutics quarterly FCF year-on-year change?
- What is United Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for United Therapeutics?
- What is United Therapeutics TTM FCF year-on-year change?
What is United Therapeutics annual free cash flow?
The current annual FCF of UTHR is $747.60 M
What is the all time high annual FCF for United Therapeutics?
United Therapeutics all-time high annual free cash flow is $747.60 M
What is United Therapeutics annual FCF year-on-year change?
Over the past year, UTHR annual free cash flow has changed by +$83.90 M (+12.64%)
What is United Therapeutics quarterly free cash flow?
The current quarterly FCF of UTHR is $300.70 M
What is the all time high quarterly FCF for United Therapeutics?
United Therapeutics all-time high quarterly free cash flow is $338.30 M
What is United Therapeutics quarterly FCF year-on-year change?
Over the past year, UTHR quarterly free cash flow has changed by +$20.20 M (+7.20%)
What is United Therapeutics TTM free cash flow?
The current TTM FCF of UTHR is $898.10 M
What is the all time high TTM FCF for United Therapeutics?
United Therapeutics all-time high TTM free cash flow is $898.10 M
What is United Therapeutics TTM FCF year-on-year change?
Over the past year, UTHR TTM free cash flow has changed by +$133.80 M (+17.51%)